Medical Access Program for Patritumab Deruxtecan (HER3-DXd, U3-1402)

If a patient suffers from a life threatening or serious disease or condition where there is an unmet medical need that cannot be met by existing therapeutic options, and the patient is ineligible or unable to take part in any ongoing clinical trial of the investigational medicine, a Medical Access Program may be opened. Medical access refers to the use of an investigational drug that is not approved by the United States Food and Drug Administration (FDA), and allows patients to access the drug outside of a clinical trial. The investigational drug is to be used only in the context of the Medical Access Program.